Allogeneic cellular vaccine
US6503503B1 · kind B1 · utility
12Cited by
3References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 13, 1997 |
| Grant date | Jan 7, 2003 |
| Priority date | — |
| Expiry date | May 13, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/57
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Vaccination with an allogeneic cell line modified with genetic material encoding specific protein antigens is an effective technique for the delivery of protein antigens to the host's antigen presentation system. The immune response generated by this vaccine is restricted by the major histocompatibility complex type of the host and not the vaccinating cell line. This immunization strategy may be used to treat or prevent tumors or infectious diseases of a mammal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.